Latest Trastuzumab Stories
Perjeta and Kadcyla are Reshaping the Treatment Algorithm for Patients with HER2-Positive Breast Cancer, According to Findings from Decision Resources Group BURLINGTON, Mass., March 25, 2014
DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/czqbv2/investigation) has announced the addition of the "Investigation
Global breast cancer survey demonstrates physicians generally prefer standard of care chemotherapy as compared to newly approved targeted therapies NEW YORK, March 11, 2014 /PRNewswire/
SEATTLE, WA and BOULDER, CO, Feb. 20, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc.
ChinaMarketResearchReports.com adds Latest Reports on Atorvastatin and Trastuzumab industry for China to its store. Dallas, TX (PRWEB) February 16, 2014
Robust Clinical Data on Filanesib Presented at ASH Supporting Announced Registration Program BOULDER, Colo., Feb. 4, 2014 /PRNewswire/ -- Array BioPharma Inc.
SEATTLE AND BOULDER, CO, Feb. 3, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY) and Array BioPharma Inc.
INCLINE VILLAGE, Nev., Feb. 3, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has entered into an agreement with Genentech, Inc. (Genentech) and F.
Availability of 150 mg formulation increases dosing convenience and flexibility MUMBAI and PITTSBURGH, Feb. 3, 2014 /PRNewswire/ -- Mylan Inc.